investments 94,103 54,012
Purchases of short-term investments (225,290) (182,449)
Purchases of property, plant and equipment (30,530) (17,674)
Capitalization of intangible assets, including
license and manufacturing access fees (1,868) (2,127)
Sale of stock holdings of Molecular Profiling
Institute, Inc. 4,100 -
Cash paid for Roche manufacturing access fees (10,000) -
Other items, net 10 (334)
Net cash used in investing activities (169,475) (148,572)
Financing activities:
Repurchase and retirement of restricted stock for
payment of taxes (1,309) (1,020)
Repurchase and retirement of common stock (9,992) -
Excess tax benefit from stock-based compensation 2,510 13,055
Proceeds from issuance of common stock 17,848 40,677
Net cash provided by financing activities 9,057 52,712
Effect of exchange rate changes on cash and cash
equivalents (198) 283
Net decrease in cash and cash equivalents (1,597) (21,017)
Cash and cash equivalents at the beginning of period 75,963 87,905
Cash and cash equivalents at the end of period $74,366 $66,888
| SOURCE Gen-Probe Incorporated Copyright©2008 PR Newswire. All rights reserved |